Clinical trials: Primary Liver Cancer
Primary Liver Cancer
Effect of Food and Formulation on the Pharmacokinetics, Safety, and Tolerability of GNS561 After One Single Dose (50 and 200mg) in Healthy Volunteers
GNS561 is a drug used in preliminary phase 1b study for treatment of patients with primary and secondary liver cancer. The formulation used was oral capsule.The objective of this study in healthy volunteers is to compare…
- Trial name
- NCT05353894
- Testing
- GNS561 oral tablets and capsules
- Where
- France
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Genoscience Pharma
Carcinoma, Hepatocellular
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in combination with sorafenib for subjects with unresectable HCC who have received no prior systemic therapy for HCC.
- Trial name
- NCT02323906
- Testing
- CC-122, Sorafenib
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Celgene
Colorectal Cancer, Carcinoma, Neuroendocrine
TheraSphere for the Treatment of Liver Metastases
This study will evaluate Liver Progression Free Survival (PFS) and safety of TheraSphere treatment at doses of 120 Gy +/1 10% in patients at least 18 years of age diagnosed with metastatic disease to the liver that cannot be…
- Conditions
- Colorectal Cancer, Carcinoma, Neuroendocrine, Neoplasm Metastasis
- Trial name
- NCT00511862
- Testing
- Yttrium 90 glass microspheres
- Where
- 5 sites in United States
- Volunteers
- 151 people
- Sponsor
- Boston Scientific Corporation
Neoplasm Metastasis
Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden
The purpose of this study is to determine the safety and tolerability of OXi4503 in subjects with relapsed or refractory carcinomas with hepatic tumor burden.
- Trial name
- OXi4503 (NCT00960557)
- Testing
- Combretastatin A1 Diphosphate (OXi4503)
- Where
- 4 sites in Australia
- Volunteers
- 16 people
- Sponsor
- Mateon Therapeutics
Stage III Breast Cancer, Stage IV Breast Cancer
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using…
- Conditions
- Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Lung Cancer, Stage IV Lung Cancer
- Trial name
- NCT04985357
- Sponsor
- Travera Inc
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
DX-8951f in Treating Patients With Biliary Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of DX-8951f in treating patients who have biliary cancer.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00005938
- Testing
- exatecan mesylate
- Where
- 5 sites in United States
- Sponsor
- Daiichi Sankyo
Cancer, Liver Cancer
Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma
The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.
- Conditions
- Cancer, Liver Cancer, Primary Liver Cancer, Hepatocellular Carcinoma
- Trial name
- PATHWAY (NCT00568308)
- Testing
- PI-88
- Where
- 10 sites in United States, Australia and 8 more
- Volunteers
- 600 people
- Sponsor
- Progen Pharmaceuticals
Primary Liver Cancer, SCLC
A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection
This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or other selected solid tumors or hematologic malignancies. The drug is given intravenously, for 5 days in a row and then two weeks off.
- Conditions
- Primary Liver Cancer, SCLC, Lymphoma, Melanoma
- Trial name
- NCT01829971
- Testing
- MRX34
- Where
- 10 sites in United States, South Korea
- Volunteers
- 155 people
- Sponsor
- Mirna Therapeutics, Inc.
Primary Liver Cancer
Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This phase I study will be conducted in HSV-seropositive subjects with advanced primary liver cancer that are refractory to conventional therapies.
- Trial name
- NCT04806464
- Testing
- Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))
- Where
- China
- Volunteers
- 44 people
- Sponsor
- CNBG-Virogin Biotech (Shanghai) Ltd.